440 related articles for article (PubMed ID: 34048142)
21. Comparative Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Serum Electrolyte Levels in Patients with Type 2 Diabetes: A Pairwise and Network Meta-Analysis of Randomized Controlled Trials.
Zhang J; Huan Y; Leibensperger M; Seo B; Song Y
Kidney360; 2022 Mar; 3(3):477-487. PubMed ID: 35582188
[TBL] [Abstract][Full Text] [Related]
22. Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis.
Min SH; Yoon JH; Hahn S; Cho YM
Diabetes Metab Res Rev; 2017 Jan; 33(1):. PubMed ID: 27155214
[TBL] [Abstract][Full Text] [Related]
23. Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors and Combined SGLT1/2 Inhibitors on Cardiovascular, Metabolic, Renal, and Safety Outcomes in Patients with Diabetes: A Network Meta-Analysis of 111 Randomized Controlled Trials.
Teo YN; Ting AZH; Teo YH; Chong EY; Tan JTA; Syn NL; Chia AZQ; Ong HT; Cheong AJY; Li TY; Poh KK; Yeo TC; Chan MY; Wong RCC; Chai P; Sia CH
Am J Cardiovasc Drugs; 2022 May; 22(3):299-323. PubMed ID: 35316484
[TBL] [Abstract][Full Text] [Related]
24. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
Scheen AJ
Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
[TBL] [Abstract][Full Text] [Related]
25. Comparative effects of sulphonylureas, dipeptidyl peptidase-4 inhibitors and sodium-glucose co-transporter-2 inhibitors added to metformin monotherapy: a propensity-score matched cohort study in UK primary care.
Wilkinson S; Williamson E; Pokrajac A; Fogarty D; Stirnadel-Farrant H; Smeeth L; Douglas IJ; Tomlinson LA
Diabetes Obes Metab; 2020 May; 22(5):847-856. PubMed ID: 31957254
[TBL] [Abstract][Full Text] [Related]
26. Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta-analysis of randomized controlled trials.
Zhao Y; Xu L; Tian D; Xia P; Zheng H; Wang L; Chen L
Diabetes Obes Metab; 2018 Feb; 20(2):458-462. PubMed ID: 28846182
[TBL] [Abstract][Full Text] [Related]
27. Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors on Cardiovascular and Metabolic Outcomes in Patients Without Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized-Controlled Trials.
Teo YH; Teo YN; Syn NL; Kow CS; Yoong CSY; Tan BYQ; Yeo TC; Lee CH; Lin W; Sia CH
J Am Heart Assoc; 2021 Feb; 10(5):e019463. PubMed ID: 33625242
[TBL] [Abstract][Full Text] [Related]
28. Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitors.
Rahelić D; Javor E; Lucijanić T; Skelin M
Ann Med; 2017 Feb; 49(1):51-62. PubMed ID: 27535028
[TBL] [Abstract][Full Text] [Related]
29. Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure.
Reed JW
Vasc Health Risk Manag; 2016; 12():393-405. PubMed ID: 27822054
[TBL] [Abstract][Full Text] [Related]
30. Sodium-glucose co-transporter-2 inhibitors and risk of adverse renal outcomes among patients with type 2 diabetes: A network and cumulative meta-analysis of randomized controlled trials.
Tang H; Li D; Zhang J; Li Y; Wang T; Zhai S; Song Y
Diabetes Obes Metab; 2017 Aug; 19(8):1106-1115. PubMed ID: 28240446
[TBL] [Abstract][Full Text] [Related]
31. Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis.
Usman MS; Siddiqi TJ; Memon MM; Khan MS; Rawasia WF; Talha Ayub M; Sreenivasan J; Golzar Y
Eur J Prev Cardiol; 2018 Mar; 25(5):495-502. PubMed ID: 29372664
[TBL] [Abstract][Full Text] [Related]
32. Effects of sodium-glucose co-transporter 2 inhibitors on liver parameters and steatosis: A meta-analysis of randomized clinical trials.
Coelho FDS; Borges-Canha M; von Hafe M; Neves JS; Vale C; Leite AR; Carvalho D; Leite-Moreira A
Diabetes Metab Res Rev; 2021 Sep; 37(6):e3413. PubMed ID: 33010191
[TBL] [Abstract][Full Text] [Related]
33. SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: a systematic review with meta-analysis of 16 randomized controlled trials.
Li WJ; Chen XQ; Xu LL; Li YQ; Luo BH
Cardiovasc Diabetol; 2020 Aug; 19(1):130. PubMed ID: 32847602
[TBL] [Abstract][Full Text] [Related]
34. Sodium-Glucose Cotransporter 2 Inhibitors and New-onset Type 2 Diabetes in Adults With Prediabetes: Systematic Review and Meta-analysis of Randomized Controlled Trials.
Mori Y; Duru OK; Tuttle KR; Fukuma S; Taura D; Harada N; Inagaki N; Inoue K
J Clin Endocrinol Metab; 2022 Dec; 108(1):221-231. PubMed ID: 36217306
[TBL] [Abstract][Full Text] [Related]
35. Sodium-glucose co-transporter-2 inhibitors as add-on therapy to insulin for type 1 diabetes mellitus: Systematic review and meta-analysis of randomized controlled trials.
Yamada T; Shojima N; Noma H; Yamauchi T; Kadowaki T
Diabetes Obes Metab; 2018 Jul; 20(7):1755-1761. PubMed ID: 29451721
[TBL] [Abstract][Full Text] [Related]
36. Evaluating the costs of glycemic response with canagliflozin versus dapagliflozin and empagliflozin as add-on to metformin in patients with type 2 diabetes mellitus in the United Arab Emirates.
Schubert A; Buchholt AT; El Khoury AC; Kamal A; Taieb V
Curr Med Res Opin; 2017 Jun; 33(6):1155-1163. PubMed ID: 28323512
[TBL] [Abstract][Full Text] [Related]
37. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis.
Toyama T; Neuen BL; Jun M; Ohkuma T; Neal B; Jardine MJ; Heerspink HL; Wong MG; Ninomiya T; Wada T; Perkovic V
Diabetes Obes Metab; 2019 May; 21(5):1237-1250. PubMed ID: 30697905
[TBL] [Abstract][Full Text] [Related]
38. Comparative safety of sodium-glucose co-transporter 2 inhibitors in elderly patients with type 2 diabetes mellitus and diabetic kidney disease: a systematic review and meta-analysis.
Liu Y; An C; Liu P; Yang F; Zhao Q
Ren Fail; 2023 Dec; 45(1):2217287. PubMed ID: 37246403
[TBL] [Abstract][Full Text] [Related]
39. Safety and efficacy of sodium glucose co-transporter 2 inhibitors combined with insulin in adults with type 1 diabetes: A meta-analysis of randomized controlled trials.
Li K; Xu G
J Diabetes; 2019 Aug; 11(8):645-655. PubMed ID: 30565398
[TBL] [Abstract][Full Text] [Related]
40. [Relative frequency of urinary tract infections in patients affected by diabetes mellitus type 2 treated with metformin and SGLT2 inhibitor.
Merész G; Szabó S; Dóczy V; Hölgyesi Á; Szakács Z
Orv Hetil; 2020 Mar; 161(13):491-501. PubMed ID: 32202151
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]